$NNVC News

Last published 3d ago

3d agoNNVCAn Investigational Drug to Tackle Measles OutbreaksACCESS NewswireNanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that it is advancing its Measles drug development program towards clinical trials. There have been three deaths in children due to Measles ...
2w agoNNVCAs Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricidesACCESS NewswireSHELTON, CT / ACCESS Newswire / October 27, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, explained today that the Phase
3w agoNNVCNanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical TrialsACCESS NewswireThe Spreading Ebola Epidemic as well as Mpox Endemic in Africa Disproportionately Impact Children; The Measles Outbreaks Primarily Impact Children SHELTON, CT / ACCESS Newswire / October 20, 2026 / NanoViricides,
1mo agoNNVCPhase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricidesACCESS NewswireSHELTON, CT / ACCESS Newswire / October 13, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, said today that its Phase IIA
1mo agoNNVCNanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026ACCESS NewswireSHELTON, CT / ACCESS Newswire / October 6, 2026 / NanoViricides, Inc. is pleased to announce that it will be presenting tomorrow October 7, 2026 at NIBA's 153rd Investment
1mo agoNNVCNanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 LivesACCESS NewswireSHELTON, CT / ACCESS Newswire / October 5, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, herewith provides additional
1mo agoNNVCNanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical TrialsACCESS NewswireSHELTON, CT / ACCESS Newswire / September 29, 2026 / NanoViricides, Inc. , reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2026 with the
1mo agoNNVCClinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricidesACCESS NewswireSHELTON, CT / ACCESS Newswire / September 28, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II
1mo agoNNVCPhase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricidesACCESS NewswireSHELTON, CT / ACCESS Newswire / September 23, 2026 / NanoViricides, Inc. today announced that the Phase II Clinical Trial of the Company's Novel Broad-Spectrum Antiviral Drug
1mo agoNNVCClinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricidesACCESS NewswireSHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II
1mo agoNNVC GILD MRNA PFE+1A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral ThreatGlobeNewswireNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can
2mo agoNNVCClinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR CongoACCESS NewswireSHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II
2mo agoNNVCWhile Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for MeaslesACCESS NewswireSHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company , and a clinical stage, leading global pioneer in the development of broad-spectrum
2mo agoNNVCThe Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin SoonACCESS NewswireSHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that the Phase
3mo agoNNVCNanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola OutbreakACCESS NewswireSHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received
3mo agoNNVCNanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the TrialACCESS NewswireSHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it is eagerly
3mo agoNNVCNanoViricides Announces Pricing of ~$3.8 Million Registered Direct OfferingACCESS NewswireSHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. , a clinical stage, leading global pioneer in the development of broad-spectrum
3mo agoNNVCAs Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for EbolaACCESS NewswireSHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has applied to
4mo agoNNVCAs Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in CongoACCESS NewswireSHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received
4mo agoNNVCResearch Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor DailyACCESS NewswireSHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a Coverage Initiating
4mo agoNNVCAs the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR CongoACCESS NewswireSHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to
4mo agoNNVCUS FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review VoucherACCESS NewswireSHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company , and a clinical stage, leading global pioneer in the development of broad-spectrum
4mo agoNNVCNanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR CongoACCESS NewswireSHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical Trial of
5mo agoNNVCAs the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR CongoACCESS NewswireSHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that its proposal to
5mo agoNNVCAs the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over AntibodiesACCESS NewswireSHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that it has proposed
5mo agoNNVCIn the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricidesACCESS NewswireSHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potential treatment options for
5mo agoNNVCNanoViricides Announces Closing of ~$2 Million Registered Direct OfferingACCESS NewswireSHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. , a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on
5mo agoNNVCEbola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricidesACCESS NewswireSHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the critical need for a
6mo agoNNVCNanoViricides Announces Pricing of ~$2 Million Registered Direct OfferingACCESS NewswireSHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. , a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on
6mo agoNNVCNanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase IIACCESS NewswireSHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. , reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2026 with the
6mo agoNNVCRecent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricidesACCESS NewswireSHELTON, CT / ACCESS Newswire / May 11, 2026 / NanoViricides, Inc. , a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the critical need for a
6mo agoNNVCNV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDAACCESS NewswireSHELTON, CT / ACCESS Newswire / May 4, 2026 / NanoViricides, Inc., a publicly traded company , and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based
6mo agoNNVCDeadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricidesACCESS NewswireSHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company , and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals
7mo agoNNVCMeasles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricidesACCESS NewswireSHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company , and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals
7mo agoNNVCPhase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricidesACCESS NewswireSHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. today announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to begin soon in the Democratic
8mo agoNNVCNanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is CompleteACCESS NewswireSHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. , a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, is pleased
9mo agoNNVCMPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricidesACCESS NewswireSHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company , and a clinical stage, leading global pioneer in the development of broad-spectrum
9mo agoNNVCMeasles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricidesACCESS NewswireSHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company , and a clinical stage, leading global pioneer in the development of broad-spectrum
9mo agoNNVCNanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam TorresACCESS NewswireSHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. , a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape,
11mo agoNNVCNanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and MeaslesACCESS NewswireSHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company , and a clinical stage, leading global pioneer in the development of
12mo agoNNVCNanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal PositionACCESS NewswireSHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. , reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending
12mo agoNNVCNanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2ACCESS NewswireSHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. , a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus
1y agoNNVCNanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market CloseACCESS NewswireSHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. , today announced the closing of its previously announced securities purchase agreement with a single
1y agoNNVCNanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market CloseACCESS NewswireSHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. , today announced that it has entered into a securities purchase agreement with a single healthcare
1y agoNNVCNanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of CongoACCESS NewswireSHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. today reported that it has received approval to Start Phase II Clinical Trial of NV-387 for the
1y agoNNVCNanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CTACCESS NewswireNV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. , a clinical stage
1y agoNNVCNanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rdACCESS NewswireSHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. , a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot
1y agoNNVCTreating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from ProactiveACCESS NewswireSHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company , announced that Nanoviricides CEO Dr Anil Diwan joined Steve Darling
1y agoNNVCNanoViricides to Present at the PODD 2025 Conference in Boston on October 27ACCESS NewswireSHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. , a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus
1y agoNNVCIn Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricidesACCESS NewswireSHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company , announced that its clinical lead drug NV-387 has shown strong